Each year there are close to 2.5 million new HIV cases worldwide. To date, there is no cure for HIV. While research on a vaccine has been going on for several decades, it will be many more years before something more practical is available. In the absence of any treatment, most patients with HIV will die within a decade.
With treatment, long-term survival is possible, but it comes at a very high cost. Those who survive are at risk for new opportunistic infections, and in many cases, pre-existing infections can reactivate and are associated with a high morbidity. Also, the use of highly active antiretroviral therapy (HAART) is associated with numerous adverse effects, drug interactions, and resistance. Many patients eventually develop lipid abnormalities and are at risk for premature atherosclerosis. With the development of a vaccine still several years away, a new way to lower the risk of new HIV infections in high-risk individuals has been advocated with the use of pre-exposure chemoprophylaxis. Since the discovery of HIV, it has been well known that sexual transmission of the virus strongly correlates with the concentration of the organism in the genital secretions and blood. Several studies have shown that the use of antiretroviral drugs can be utilized to lower the infectivity of high-risk patients by decreasing the concentration of the organism from blood and genital secretions. Today, use of pre-exposure chemoprophylaxis is no longer just a hypothesis but a clinical application that helps to decrease the number of new cases of HIV.
Pre-Exposure Chemoprophylaxis for Prevention of HIV
Pre-exposure chemoprophylaxis is a relatively new concept that consists of daily intake of antiretroviral medications that protect high-risk individuals from HIV infection. Several trials have shown that when pre-exposure chemoprophylaxis is closely monitored for adherence, it is an effective method to reduce the risk of HIV infection, almost to zero. This new concept is now seen as a more effective way of preventing HIV infection than treating the individual after exposure.
The important thing to note is that pre-exposure chemoprophylaxis is only effective against HIV and does not provide protection against any other sexually transmitted infection (STI), hepatitis, or blood-borne infections. The critical feature of this regimen is that adherence to medication must be total. Individuals who regularly miss doses of their medication will be at high risk for acquiring HIV. Thus, pre-exposure chemoprophylaxis for HIV prevention is part of a combination package that also includes support, sex education, and advice about the importance of adherence to treatment.
The idea that preexposure chemoprophylaxis to prevent HIV infection has gained momentum from the following observations:
HIV is a retrovirus that replicates primarily in CD4+ T cells and macrophages. HIV can be transmitted via blood, blood products, sexual fluids, and breast milk. Most people are infected with HIV through sexual contact, before birth or during delivery, during breastfeeding, or when sharing contaminated syringes.
Who is in need of pre-exposure chemoprophylaxis?
Based on guidelines issued by the Centers for Disease Control and Prevention (CDC), a fixed-dose combination of tenofovir (300 mg) and emtricitabine (200 mg) taken once daily is effective and safe in decreasing the risk of HIV infection in adults (CDC, 2014). Before starting pre-exposure chemoprophylaxis for HIV, one first needs to identify the high-risk individual. In general, high-risk individuals include the following groups of people:
As part of a comprehensive STD prevention program, pre-exposure chemoprophylaxis is only effective if it is administered as a package of STD-prevention services. These individuals need comprehensive education on sexual behavior, safe sex, use of condoms, regular HIV testing, reproductive health services, counseling, contraception counseling, and frequent STD checks. Pre-exposure chemoprophylaxis may be a more effective and safer way to prevent HIV when it is used in the following ways:
World Health Organization (WHO) Recommendations
Several years ago, the WHO also recognized the benefits of pre-exposure chemoprophylaxis and has now issued new guidelines that recommend this treatment to anyone who is at high risk for HIV infection, as part of the combination HIV-prevention program (WHO, 2015). Prior to 2015, pre-exposure chemoprophylaxis was only recommended to a specific group of individuals like men who have sex other men, sex workers, and individuals who inject illicit drugs. According to UNAIDS, high-risk populations that may benefit from pre-exposure chemoprophylaxis are those groups with an HIV incidence rate of about 3 per 100 person-years or higher. The United Nations 2016 Declaration on HIV and AIDs included a commitment to provide at least 3 million high-risk individuals with pre-exposure chemoprophylaxis by 2020. As of 2016, only 100,000 people have enrolled in this initiative. While a significant number of people on pre-exposure chemoprophylaxis reside in the United States, a high number of individuals living outside the continental United States are also candidates but lack the finances to buy the medications or do not have access to the medications.
Tenofovir/emtricitabine has been studied in several trials that involved pregnant women. The limited data available indicate that the regimen is safe and does not lead to any adverse outcomes in the newborn. However, the priority is always non-drug therapy to reduce the risk of HIV infection in pregnant women. Even though current short-term data indicate that the pre-exposure chemoprophylaxis with tenofovir/emtricitabine is safe in pregnancy, all patients should be cautioned about the possibility of adverse outcomes. Tenofovir/emtricitabine is known to pass into breast milk.
Overall, tenofovir/emtricitabine is well tolerated by most individuals. However, some people may experience the following adverse effects:
Rare, Serious Adverse Effects
Potential for Drug Interactions
Tenofovir is known to interact with other antiretroviral drugs. When coadministered with these agents, the following may occur:
Recent studies show that patients taking tenofovir/emtricitabine should not combine it with high doses of non-steroidal anti-inflammatory drugs, as this can lead to new onset or worsening of renal impairment.
What is the cost of tenofovir/emtricitabine?
In the United States, the retail cost for a 30-day supply of this drug combination varies from $1400 to $1600. In Canada, the cost is anywhere from $800 to $1200, and unlike in the United States, most insurers do not cover the cost. Outside of North America, the cost per pill has been subsidized in Asia and Africa and varies from $0.20 to $0.40, which averages to about $8 to $15 a month, still a large sum in poverty-stricken areas of Africa and Asia.
Several programs make tenofovir/emtricitabine more affordable by offering assistance with medication costs, co-payments, and insurance. However, patients should search out the best possible options because irrespective of what insurance is selected, the annual cost of this combination drug is expensive. The company that manufactures tenofovir/emtricitabine does have several programs for individuals who are unable to buy the product. Most US insurers cover the cost of tenofovir/emtricitabine, but the co-payments are very high. For those without insurance, some medication-assistance programs make the drug combination available for free. Outside of North America and Europe, the cost of tenofovir/emtricitabine is prohibitively expensive, and most people cannot afford it.
A history of HIV exposure followed by diagnostic confirmation.
Screening for human immunodeficiency virus infection is important because infected individuals may remain asymptomatic for years. Serologic tests evaluate for HIV infection. The following secondary testing may be performed to assist with diagnosis or staging:
At the moment, the only antiretroviral combination approved for pre-exposure chemoprophylaxis is tenofovir/emtricitabine. Tenofovir not only has a long half-life, but it also is safe, relatively inexpensive, and can be found in high concentrations in macrophages, monocytes, and genital secretions. The few clinical trials that have taken place have involved tenofovir with or without emtricitabine. The combination of tenofovir/emtricitabine was approved several years ago for pre-exposure chemoprophylaxis against HIV in men who have sex with men, as well as for heterosexually-active, serodiscordant men and women.
Another agent that could potentially be used in pre-exposure chemoprophylaxis is maraviroc. The drug is classified as a CCR5 co-receptor antagonist. It is known to achieve high concentrations in rectal and genital secretions. Plans are to study the drug in future clinical trials.
Pre-Exposure Chemoprophylaxis Pilot Programs
To ensure that pre-exposure chemoprophylaxis is safe and effective many pilot programs have been conducted both in the United States and abroad. It is one of the first pilot programs implemented in San Francisco in 2012. Over the past five years, data indicates high adherence and no new HIV infections among the individuals who have participated. The San Francisco program also has a website that sends reminders about the importance of medication adherence to new clients.
Another program with high success is one in Brazil that has focused on men who have sex with men and transgender women. In 2011, only 22% of men who have sex with men had heard about the program, but over the next four years participation grew to 60%, and it is anticipated that it will reach 95% in the next 12 months. Unlike other countries, Brazil is offering free, pre-exposure chemoprophylaxis to those who cannot afford it (WHO, 2015).
Other similar programs have taken place Zimbabwe, Kenya, Uganda, and South Africa. A key feature of the African program is offering legal advice and informing sex workers of their basic human rights. The limited data available indicate that the programs seem to be working and not many new cases of HIV are being reported in the individuals who have participated (WHO, 2015).
Concerns with Pre-Exposure Chemoprophylaxis
While there are many advantages to using pre-exposure chemoprophylaxis to prevent HIV in high-risk patients, experts state that the following points need to be kept in mind:
Monitoring After Initiation Pre-Exposure Chemoprophylaxis
When an individual is prescribed tenofovir/emtricitabine as part of pre-exposure chemoprophylaxis, healthcare workers should do the following:
Pre-exposure chemoprophylaxis is significantly less costly than the actual treatment of HIV infection, both in terms of duration of use and per dose. Pre-exposure chemoprophylaxis is prescribed to high-risk individuals and is supposed to be taken daily until the risk factors diminish; whereas, those who acquire HIV need lifelong HAART to prolong life. Further, HAART consists of multiple drug combinations which are prohibitively expensive; whereas pre-exposure chemoprophylaxis uses only one drug combination, which is relatively less costly. Unfortunately, surveys conducted by the CDC reported that in 21 out of the 31 countries, the cost of pre-exposure chemoprophylaxis was a major factor in the wider implementation of this treatment regimen (CDC, 2014). Infectious disease experts state that ultimately the cost-effectiveness of pre-exposure chemoprophylaxis will be determined by the final retail cost of the medication and how efficiently it can be delivered to the individuals who need it the most.
Demand for Pre-Exposure Chemoprophylaxis
While delivering pre-exposure chemoprophylaxis to prevent HIV is an admirable goal, what exactly is the demand? A recent multi-country survey of individuals at high-risk for HIV indicated that at least 70% of participants would most definitely use the treatment if it were available. In addition, another study from India revealed that close to 90% of men who have sex with men would use pre-exposure chemoprophylaxis if it were readily available.
Another study from the United Kingdom revealed that nearly 50% of men who have sex with men showed an interest in pre-exposure chemoprophylaxis, and it is believed that such an approach could prevent close to 7000 new HIV infections by the year 2020 (NHS, 2017).
Similar findings have been noted in Latin America among men who have sex with men, sex workers, and transgender women. Unfortunately in Latin America, despite the huge demand, only Brazil has a publicly available pre-exposure chemoprophylaxis program (WHO, 2017).
In England, the National Health Service has started to provide individual access to pre-exposure chemoprophylaxis in small clinical trials, which has led many other individuals to purchase generic versions of tenofovir and emtricitabine from online sources. Further, the British Council for Drug Safety has analyzed the online antiretroviral drugs and found them to be of similar quality and as effective as those sold in retail stores (NHS, 2017).
For pre-exposure chemoprophylaxis to be successful, medication adherence is vital. While short-term clinical trials under controlled conditions have shown high adherence rates, data from outpatient clinics (outside of clinical trials) reveal that adherence can vary from 13% to 52%.
Factors that lead to low adherence include the following:
Some clinics have started to use cognitive behavioral therapy for patients at risk for low adherence to improve adherence. So far there are no data to determine if this therapy can change the adherence rates. Two clinical trials are underway using a long-acting injectable antiretroviral formula to avoid the low adherence.
For individuals who have limited options for protecting themselves against HIV, pre-exposure chemoprophylaxis is both cost-effective and practical.
Several large trials have been conducted on pre-exposure chemoprophylaxis. In almost every study the risk of acquiring HIV was significantly lowered by 54% to 90%. In fact, if the data only included individuals who adhered to medication use, then the effectiveness of this drug combination is close to 100%. The most well-publicized PROUD trial conducted in the United Kingdom revealed that pre-exposure chemoprophylaxis decreased the risk of HIV transmission by 86% and there were no negative changes in the sexual behavior of the participants.
The first pre-exposure chemoprophylaxis studies were done in 2007, and since then many other studies have reported similar benefits. Data from France, Canada, Kenya, South Africa, and Uganda show that use of tenofovir/emtricitabine significantly decreases the risk of HIV in different scenarios. More importantly, these studies have not shown that use of pre-exposure chemoprophylaxis leads to reduced use of a condom or high-risk sexual behavior. The PROUD study conducted in the United Kingdom found no difference in the number of STDs or condom usage among individuals who were treated with pre-exposure chemoprophylaxis and those who were not treated. Fortunately, the few observational studies have not shown that high-risk sexual behavior occurs in the short term, but there are no data on long-term behavior.
Despite awareness of the benefits of pre-exposure chemoprophylaxis, there remain many challenges ahead. Data suggest that less than 5% to 10% of high-risk individuals have access to this therapy in the United States and even fewer outside of North America. In the United States, despite the approval for pre-exposure chemoprophylaxis in 2012, universal adoption has been slow. Similarly, in Europe, the number of individuals at high-risk for HIV have not participated in the treatment by the thousands; they only number in the hundreds. Another US study showed that awareness of pre-exposure chemoprophylaxis in the United States is lowest among young black men who have sex with men.
Pre-exposure chemoprophylaxis has been fully approved in Australia, Brazil, Canada, and several African and European countries, but drug availability is a problem. In some countries, the drug regimen is too expensive, and in other countries, there are are no national guidelines established, which makes it difficult for healthcare workers to prescribe the treatment. Finally, in many countries, despite having a national healthcare system, the drug regimen often is not available for free. Even in Canada, with its well-established, free healthcare system, this drug regimen is not free, but there are plans to cover it under the universal healthcare system in the future.
The other limiting factor is lack of knowledge among healthcare workers about the availability of this treatment. While awareness has increased over the past five years among infectious disease experts, most other healthcare workers outside this specialty remain unaware.
To improve accessibility, in California, patients can get a prescription for pre-exposure chemoprophylaxis via a mobile app without even having to see a healthcare worker. The individual enters their data into an app, and the information is transmitted to a healthcare worker who then determines if the treatment is suitable. Of course, before a prescription is sent to the pharmacy, the individual must undergo blood testing to make sure that he or she is HIV negative.
In South Africa, two pilot programs called UChoose and PlusPills have been developed to reach out to young people who are at high risk for acquiring HIV.
The one other factor that has limited the use of pre-exposure chemoprophylaxis is that many people who could benefit from this treatment are not aware of it. Countless surveys done in Europe, Africa, and the United States indicated that only 30% of young men who have sex with men have heard about pre-exposure chemoprophylaxis. Individuals more likely to have heard about it usually are older, have some health insurance, are better educated, or reported as having acquired at least one STD in the past. (Level V)
|||Buttram ME,Kurtz SP, Representations of Pre-exposure Prophylaxis, Informal Antiretroviral Medication Use for HIV Prevention, and Diversion on Geosocial Networking Apps among Men Who Have Sex with Men. AIDS and behavior. 2018 Sep 25 [PubMed PMID: 30255385]|
|||Mitsch A,Singh S,Li J,Balaji A,Linley L,Selik R, Age-Associated Trends in Diagnosis and Prevalence of Infection with HIV Among Men Who Have Sex with Men - United States, 2008-2016. MMWR. Morbidity and mortality weekly report. 2018 Sep 21 [PubMed PMID: 30235184]|
|||Garnett GP,Krishnaratne S,Harris KL,Hallett TB,Santos M,Enstone JE,Hensen B,Dallabetta G,Revill P,Gregson SAJ,Hargreaves JR, Cost-Effectiveness of Interventions to Prevent HIV Acquisition null. 2017 Nov 3 [PubMed PMID: 30212104]|
|||Abbasi J, HIV Preexposure Prophylaxis [PubMed PMID: 30208436]|
|||Patel VV,Ginsburg Z,Golub SA,Horvath KJ,Rios N,Mayer KH,Kim RS,Arnsten JH, Empowering With PrEP (E-PrEP), a Peer-Led Social Media-Based Intervention to Facilitate HIV Preexposure Prophylaxis Adoption Among Young Black and Latinx Gay and Bisexual Men: Protocol for a Cluster Randomized Controlled Trial. JMIR research protocols. 2018 Aug 28 [PubMed PMID: 30154071]|
|||Weiss G,Smith DK,Newman S,Wiener J,Kitlas A,Hoover KW, PrEP implementation by local health departments in US cities and counties: Findings from a 2015 assessment of local health departments. PloS one. 2018 [PubMed PMID: 30044820]|
|||Saag MS,Benson CA,Gandhi RT,Hoy JF,Landovitz RJ,Mugavero MJ,Sax PE,Smith DM,Thompson MA,Buchbinder SP,Del Rio C,Eron JJ Jr,Fätkenheuer G,Günthard HF,Molina JM,Jacobsen DM,Volberding PA, Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018 Jul 24 [PubMed PMID: 30043070]|
|||Koss CA,Ayieko J,Mwangwa F,Owaraganise A,Kwarisiima D,Balzer LB,Plenty A,Sang N,Kabami J,Ruel TD,Black D,Camlin CS,Cohen CR,Bukusi EA,Clark TD,Charlebois ED,Petersen ML,Kamya MR,Havlir DV, Early Adopters of HIV Preexposure Prophylaxis in a Population-based Combination Prevention Study in Rural Kenya and Uganda. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 May 5 [PubMed PMID: 29741594]|
|||Mitchell KM,Dimitrov D,Hughes JP,Xia F,Donnell D,Amico KR,Bokoch K,Chitwarakorn A,Bekker LG,Holtz TH,Mannheimer S,Grant RM,Boily MC, In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs? AIDS (London, England). 2018 Mar 27 [PubMed PMID: 29424774]|
|||Marcus JL,Levine K,Grasso C,Krakower DS,Powell V,Bernstein KT,Boswell S,Mayer KH, HIV Preexposure Prophylaxis as a Gateway to Primary Care. American journal of public health. 2018 Oct [PubMed PMID: 30024802]|
|||Luz PM,Benzaken A,Alencar TM,Pimenta C,Veloso VG,Grinsztejn B, PrEP adopted by the brazilian national health system: What is the size of the demand? Medicine. 2018 May [PubMed PMID: 29794605]|
|||Summary of Guidelines for the Use of Pre-Exposure Prophylaxis for HIV in Korea. Infection [PubMed PMID: 29027392]|
|||Pollock L,Levison J, Role of Preexposure Prophylaxis in the Reproductive Health of Women at Risk for Human Immunodeficiency Virus Infection. Obstetrics and gynecology. 2018 Sep [PubMed PMID: 30095764]|
|||Bhatia R,Modali L,Lowther M,Glick N,Bell M,Rowan S,Keglovitz K,Schneider J, Outcomes of Preexposure Prophylaxis Referrals From Public STI Clinics and Implications for the Preexposure Prophylaxis Continuum. Sexually transmitted diseases. 2018 Jan [PubMed PMID: 28876282]|
|||Hosek SG,Landovitz RJ,Kapogiannis B,Siberry GK,Rudy B,Rutledge B,Liu N,Harris DR,Mulligan K,Zimet G,Mayer KH,Anderson P,Kiser JJ,Lally M,Brothers J,Bojan K,Rooney J,Wilson CM, Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. JAMA pediatrics. 2017 Nov 1 [PubMed PMID: 28873128]|
|||Janes H,Corey L,Ramjee G,Carpp LN,Lombard C,Cohen MS,Gilbert PB,Gray GE, Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. AIDS research and human retroviruses. 2018 Aug [PubMed PMID: 29732896]|
|||Zablotska IB,O'Connor CC, Preexposure Prophylaxis of HIV Infection: the Role of Clinical Practices in Ending the HIV Epidemic. Current HIV/AIDS reports. 2017 Dec [PubMed PMID: 29071519]|